Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Conditions:   Bile Duct Cancer;   Gall Bladder Cancer;   Breast Cancer;   Neuroendocrine Tumors;   Ovarian Cancer;   Pancreatic Adenocarcinoma;   Soft Tissue Sarcoma;   Vulvar Cancer;   Prostate Cancer
Interventions:   Drug: Atezolizumab;   Drug: Tivozanib
Sponsors:   University of Florida;   Genentech, Inc.;   Aveo Oncology Pharmaceuticals
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 30, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments